Cargando…
A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro
We recently discovered a superantigen-like motif sequentially and structurally similar to a staphylococcal enterotoxin B (SEB) segment, near the S1/S2 cleavage site of the SARS-CoV-2 spike protein, which might explain the multisystem inflammatory syndrome (MIS-C) observed in children and the cytokin...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082696/ https://www.ncbi.nlm.nih.gov/pubmed/33930306 http://dx.doi.org/10.1016/j.str.2021.04.005 |
_version_ | 1783685890718040064 |
---|---|
author | Cheng, Mary Hongying Porritt, Rebecca A. Rivas, Magali Noval Krieger, James M. Ozdemir, Asli Beyza Garcia, Gustavo Arumugaswami, Vaithilingaraja Fries, Bettina C. Arditi, Moshe Bahar, Ivet |
author_facet | Cheng, Mary Hongying Porritt, Rebecca A. Rivas, Magali Noval Krieger, James M. Ozdemir, Asli Beyza Garcia, Gustavo Arumugaswami, Vaithilingaraja Fries, Bettina C. Arditi, Moshe Bahar, Ivet |
author_sort | Cheng, Mary Hongying |
collection | PubMed |
description | We recently discovered a superantigen-like motif sequentially and structurally similar to a staphylococcal enterotoxin B (SEB) segment, near the S1/S2 cleavage site of the SARS-CoV-2 spike protein, which might explain the multisystem inflammatory syndrome (MIS-C) observed in children and the cytokine storm in severe COVID-19 patients. We show here that an anti-SEB monoclonal antibody (mAb), 6D3, can bind this viral motif at its polybasic (PRRA) insert to inhibit infection in live virus assays. The overlap between the superantigenic site of the spike and its proteolytic cleavage site suggests that the mAb prevents viral entry by interfering with the proteolytic activity of cell proteases (furin and TMPRSS2). The high affinity of 6D3 for this site originates from a polyacidic segment at its heavy chain CDR2. The study points to the potential utility of 6D3 for possibly treating COVID-19, MIS-C, or common colds caused by human coronaviruses that also possess a furin-like cleavage site. |
format | Online Article Text |
id | pubmed-8082696 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80826962021-04-29 A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro Cheng, Mary Hongying Porritt, Rebecca A. Rivas, Magali Noval Krieger, James M. Ozdemir, Asli Beyza Garcia, Gustavo Arumugaswami, Vaithilingaraja Fries, Bettina C. Arditi, Moshe Bahar, Ivet Structure Article We recently discovered a superantigen-like motif sequentially and structurally similar to a staphylococcal enterotoxin B (SEB) segment, near the S1/S2 cleavage site of the SARS-CoV-2 spike protein, which might explain the multisystem inflammatory syndrome (MIS-C) observed in children and the cytokine storm in severe COVID-19 patients. We show here that an anti-SEB monoclonal antibody (mAb), 6D3, can bind this viral motif at its polybasic (PRRA) insert to inhibit infection in live virus assays. The overlap between the superantigenic site of the spike and its proteolytic cleavage site suggests that the mAb prevents viral entry by interfering with the proteolytic activity of cell proteases (furin and TMPRSS2). The high affinity of 6D3 for this site originates from a polyacidic segment at its heavy chain CDR2. The study points to the potential utility of 6D3 for possibly treating COVID-19, MIS-C, or common colds caused by human coronaviruses that also possess a furin-like cleavage site. Elsevier Ltd. 2021-09-02 2021-04-29 /pmc/articles/PMC8082696/ /pubmed/33930306 http://dx.doi.org/10.1016/j.str.2021.04.005 Text en © 2021 Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Cheng, Mary Hongying Porritt, Rebecca A. Rivas, Magali Noval Krieger, James M. Ozdemir, Asli Beyza Garcia, Gustavo Arumugaswami, Vaithilingaraja Fries, Bettina C. Arditi, Moshe Bahar, Ivet A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro |
title | A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro |
title_full | A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro |
title_fullStr | A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro |
title_full_unstemmed | A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro |
title_short | A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro |
title_sort | monoclonal antibody against staphylococcal enterotoxin b superantigen inhibits sars-cov-2 entry in vitro |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082696/ https://www.ncbi.nlm.nih.gov/pubmed/33930306 http://dx.doi.org/10.1016/j.str.2021.04.005 |
work_keys_str_mv | AT chengmaryhongying amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT porrittrebeccaa amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT rivasmagalinoval amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT kriegerjamesm amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT ozdemiraslibeyza amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT garciagustavo amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT arumugaswamivaithilingaraja amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT friesbettinac amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT arditimoshe amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT baharivet amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT chengmaryhongying monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT porrittrebeccaa monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT rivasmagalinoval monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT kriegerjamesm monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT ozdemiraslibeyza monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT garciagustavo monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT arumugaswamivaithilingaraja monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT friesbettinac monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT arditimoshe monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT baharivet monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro |